Spotlight on Internal Medicine
Immune-Mediated Inflammatory Disease Curbside Consults: Psoriasis – New and Emerging Options for Disease Management
StartActivity Details
Expires: October 18, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is dermatologists, gastroenterologists, rheumatologists, and other health care professionals involved in the management of patients with immune-mediated inflammatory diseases.
Learning Objective
Upon successful completion of this activity, participants should be better able to select treatment for patients with psoriasis based on the latest clinical evidence and recommendations.
Activity Description
In this Curbside Consult video, Drs. Leonard Calabrese and Anthony Fernandez discuss new and emerging treatment options for a patient with persistent moderate psoriasis despite ongoing therapy.
Activity Chair
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Disclosures:
Consulting Fee: AbbVie, Amgen, Bristol Myers Squibb, Crescendo, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Kiniksa, Lilly, Pfizer, Sanofi-Regeneron, UCB
Speakers Bureau: AbbVie, Bristol Myers Squibb, Crescendo, Genentech, Horizon, Sanofi, UCB
Faculty
Director of Medical Dermatology
W.D. Steck Chair of Clinical Dermatology
Departments of Dermatology and Pathology
Co-Medical Director of Continuing Medical Education
Cleveland Clinic
Cleveland, OH
Disclosures:
Consulting Fee: AbbVie, Actellion, Mallinkrodt, Novartis, UCB
Speakers Bureau: AbbVie, Mallinkrodt, Novartis
Contracted Research: Mallinkrodt, Novartis
Research Support for Clinical Trials: Corbus, Pfizer
Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosures: No relevant financial relationships to
disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, October 19, 2020 to October 18, 2021.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objective, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by educational grants from AbbVie Inc. and Genentech, Inc.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com.
Activity Details
Expires: October 18, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is dermatologists, gastroenterologists, rheumatologists, and other health care professionals involved in the management of patients with immune-mediated inflammatory diseases.
Learning Objective
Upon successful completion of this activity, participants should be better able to select treatment for patients with psoriasis based on the latest clinical evidence and recommendations.
Activity Description
In this Curbside Consult video, Drs. Leonard Calabrese and Anthony Fernandez discuss new and emerging treatment options for a patient with persistent moderate psoriasis despite ongoing therapy.
Activity Chair
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Disclosures:
Consulting Fee: AbbVie, Amgen, Bristol Myers Squibb, Crescendo, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Kiniksa, Lilly, Pfizer, Sanofi-Regeneron, UCB
Speakers Bureau: AbbVie, Bristol Myers Squibb, Crescendo, Genentech, Horizon, Sanofi, UCB
Faculty
Director of Medical Dermatology
W.D. Steck Chair of Clinical Dermatology
Departments of Dermatology and Pathology
Co-Medical Director of Continuing Medical Education
Cleveland Clinic
Cleveland, OH
Disclosures:
Consulting Fee: AbbVie, Actellion, Mallinkrodt, Novartis, UCB
Speakers Bureau: AbbVie, Mallinkrodt, Novartis
Contracted Research: Mallinkrodt, Novartis
Research Support for Clinical Trials: Corbus, Pfizer
Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosures: No relevant financial relationships to
disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, October 19, 2020 to October 18, 2021.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objective, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by educational grants from AbbVie Inc. and Genentech, Inc.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com.
Internal Medicine Presentations
Improving Cardiovascular Outcomes by Decreasing Residual Risk: Take the Wheel of Knowledge Challenge
StartActivity Details
ABIM MOC
Expires: February 11, 2022
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is cardiologists, internists, and other health care professionals involved in the management of patients with, or at risk for cardiovascular disease.
Learning Objectives
Upon successful completion of this educational activity, participants should be better able to:
- Utilize appropriate methods to assess residual risk in patients with
controlled low-density lipoprotein cholesterol
(LDL-C). - Evaluate the latest clinical evidence regarding cardiovascular outcomes trials and the implications for primary and secondary prevention.
- Identify patients who may benefit from additional treatment to reduce cardiovascular risk despite the management of other risk factors and manage them accordingly.
Activity Description
Cardiovascular disease (CVD) continues to be the leading cause of preventable death in the United States, despite therapeutic advances. Because hyperlipidemia is a major risk factor for CVD, the treatment of elevated cholesterol, particularly low-density lipoprotein cholesterol (LDL-C), has been a major focus of preventive therapy. Notably, high triglyceride levels are independently associated with an increased risk of CVD after adjustment for LDL-C levels. Patients presenting with hypertriglyceridemia may also have multiple CVD risk factors. Increasingly, cardiologists have recognized that patients with hypertriglyceridemia experience residual CVD risk and adverse cardiovascular events. Cardiologists and other health care professionals are now rethinking their treatment regimens in light of new findings from cardiovascular outcomes trials. In addition, new evidence continues to emerge regarding cardioprotective mechanisms that underlie newer medications for CVD risk reduction. In this Wheel of Knowledge Challenge, an interactive quiz of knowledge and confidence, your knowledge will be tested on the latest clinical developments and management strategies for patients with, or at risk for, cardiovascular disease. This medical education program will address methods for assessing residual risk in patients with controlled LDL-C. The latest clinical evidence regarding cardiovascular outcomes trials and the implications for primary and secondary prevention are also considered, along with methods for identifying patients who may benefit from additional treatment to reduce cardiovascular risk.
Faculty
Professor of Medicine, Cardiology
Director, Seinsheimer Cardiovascular Health Program
The Medical University of South Carolina
Charleston, SC
Disclosure:
Consulting Fee: Amgen, Esperion
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control.
Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this
CME activity enables the participant to earn up to 0.50 Medical Knowledge MOC
points in the American Board of Internal Medicine’s (ABIM) Maintenance of
Certification (MOC) program. It is the CME activity provider’s responsibility
to submit participant completion information to ACCME for the purpose of
granting ABIM MOC credit.
Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.
This enduring material is approved for 1 year from the date of original release, February 12, 2021 to February 11, 2022.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Amarin Pharma Inc.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com.
Activity Details
ABIM MOC
Expires: February 11, 2022
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is cardiologists, internists, and other health care professionals involved in the management of patients with, or at risk for cardiovascular disease.
Learning Objectives
Upon successful completion of this educational activity, participants should be better able to:
- Utilize appropriate methods to assess residual risk in patients with
controlled low-density lipoprotein cholesterol
(LDL-C). - Evaluate the latest clinical evidence regarding cardiovascular outcomes trials and the implications for primary and secondary prevention.
- Identify patients who may benefit from additional treatment to reduce cardiovascular risk despite the management of other risk factors and manage them accordingly.
Activity Description
Cardiovascular disease (CVD) continues to be the leading cause of preventable death in the United States, despite therapeutic advances. Because hyperlipidemia is a major risk factor for CVD, the treatment of elevated cholesterol, particularly low-density lipoprotein cholesterol (LDL-C), has been a major focus of preventive therapy. Notably, high triglyceride levels are independently associated with an increased risk of CVD after adjustment for LDL-C levels. Patients presenting with hypertriglyceridemia may also have multiple CVD risk factors. Increasingly, cardiologists have recognized that patients with hypertriglyceridemia experience residual CVD risk and adverse cardiovascular events. Cardiologists and other health care professionals are now rethinking their treatment regimens in light of new findings from cardiovascular outcomes trials. In addition, new evidence continues to emerge regarding cardioprotective mechanisms that underlie newer medications for CVD risk reduction. In this Wheel of Knowledge Challenge, an interactive quiz of knowledge and confidence, your knowledge will be tested on the latest clinical developments and management strategies for patients with, or at risk for, cardiovascular disease. This medical education program will address methods for assessing residual risk in patients with controlled LDL-C. The latest clinical evidence regarding cardiovascular outcomes trials and the implications for primary and secondary prevention are also considered, along with methods for identifying patients who may benefit from additional treatment to reduce cardiovascular risk.
Faculty
Professor of Medicine, Cardiology
Director, Seinsheimer Cardiovascular Health Program
The Medical University of South Carolina
Charleston, SC
Disclosure:
Consulting Fee: Amgen, Esperion
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control.
Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this
CME activity enables the participant to earn up to 0.50 Medical Knowledge MOC
points in the American Board of Internal Medicine’s (ABIM) Maintenance of
Certification (MOC) program. It is the CME activity provider’s responsibility
to submit participant completion information to ACCME for the purpose of
granting ABIM MOC credit.
Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.
This enduring material is approved for 1 year from the date of original release, February 12, 2021 to February 11, 2022.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Amarin Pharma Inc.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com.
Research Updates in Gout: Improving Response Rate to Therapy
StartActivity Details
Expires: February 11, 2022
Accredited By
Target Audience
Rheumatologists, nephrologists, and other healthcare professionals involved in the care of patients with gout.
Learning Objectives
- Summarize the latest evidence related to combination pharmacologic treatment of patients with gout who do not achieve the target serum urate level with monotherapy
- Summarize the latest evidence related to complications associated with gout
- Incorporate evidence-based research into clinical practice
Activity Description
OVERVIEW
Dr. Brian Mandell and Dr. Naomi Schlesinger discuss recent published evidence
related to gout, as well as study results presented at the American College
of Rheumatology Convergence 2020 virtual annual meeting. Dr. Schlesinger
begins with an introduction to this CME activity by touching on a recent
published systematic review indicating that the manifestations of gout extend
beyond the joints, affecting other organs and tissues. Dr. Schlesinger also
provides an overview of some of the challenges encountered in clinical
practice with the use of urate-lowering therapy. In module 1, Dr. Schlesinger
focuses on 2 abstracts presented at ACR Convergence 2020 concerning
gout-related comorbidities, particularly cardiovascular disease. In module 2,
Dr. Mandell focuses on 2 abstracts related to the safety and use of
urate-lowering therapy, specifically allopurinol, febuxostat, and
pegloticase. In module 3, Dr. Mandell discusses 2 abstracts related to the
systemic nature of gout; 1 abstract focuses on heart failure, while the other
focuses on the lumbar spine.
CONTENT AREAS
- Systemic burden of gout
- Gout comorbidities
- Allopurinol
- Febuxostat
- Pegloticase
Statement of Educational Need
- Increased understanding of the safety and efficacy of combination treatment with medications with different mechanisms for lowering the serum urate level
- Increased understanding of updated recommendations regarding the use of combination urate-lowering therapy
- Increased understanding of the association of gout with systemic complications involving the heart, kidneys, and other organs
Agenda
Modules will be structured and recorded in a manner that best supports the nature of the data published by each study. In general, this structure will be:
- Faculty welcomes the learner, introduces the study, states why the study was included in this program [1 min]
- Faculty reviews study methodology [1 min]
- For emphasis or clarity, charts, graphs, or PowerPoint slides may be edited into the final video
- Faculty summarizes key findings [3-4 min]
- How the data advances the current treatment landscape/paradigms
- How the data should be positioned among ongoing research
- How the data connects with current research imperatives
- Clinical significance/implications for current knowledge or practice
- Data one might be expected from the trial in the future
- Faculty provides commentary [5-8 min]
Note: this structure may vary slightly when two smaller studies or abstracts are presented in the same module.
Faculty
Professor of Medicine
Chairman of Academic Medicine
Cleveland Clinic
Cleveland, Ohio
Professor of Medicine
Chief, Division of Rheumatology
UMDNJ-Robert Wood Johnson Medical School
New Brunswick, New Jersey
Conflict of Interest Policy/Disclosure Statement
It is the policy of the Annenberg Center for Health Sciences to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty and planners participating in sponsored programs are expected to identify and reference off-label product use and disclose any relationship with those supporting the activity or any others with products or services available within the scope of the topic being discussed in the educational presentation.
The Annenberg Center for Health Sciences assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE/CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CE/CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.
In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center for Health Sciences policy, the following disclosures have been made:
Faculty
Brian Mandell, MD, PhD
Consultant: Horizon
Data Monitoring Safety Board: Horizon
Speakers Bureau: Genentech
Naomi Schlesinger, MD
Advisory Board: IFM, Johnson and Johnson
Research Support: Amgen, Pfizer
Speakers Bureau: Horizon
Accreditation Statement
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
This activity is an online enduring material. Successful completion is achieved by reading and/or viewing the materials, reflecting on its implications in your practice, and completing the assessment component.
The estimated time to complete the activity is 1.0 hour.
Statement of Commercial Support
This activity is supported by an educational grant from Horizon Therapeutics.
Disclaimer Statement/Disclosure of Unlabeled Use
The faculty for this activity have disclosed that there will be no discussion about the use of products for non-FDA approved applications.
Additional content planners
The following have no significant relationship to disclose:
Greg Scott, PharmD (Medical writer)
Eugene Cullen, MD (Peer Reviewer)
Annenberg Center for Health Sciences
Staff at the Annenberg Center for Health Sciences at Eisenhower have no
relevant commercial relationships to disclose.
The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient’s unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.
Contact Information for Questions About the Activity
For help or questions about this activity please contact Continuing
Education:
ce@annenberg.net
Annenberg Center for Health Sciences
39000 Bob Hope Drive
Dinah Shore Building
Rancho Mirage, CA 92270
Phone 760-773-4500
Fax 760-773-4513
8 AM – 5 PM, Pacific Time, Monday – Friday
Activity Details
Expires: February 11, 2022
Accredited By
Target Audience
Rheumatologists, nephrologists, and other healthcare professionals involved in the care of patients with gout.
Learning Objectives
- Summarize the latest evidence related to combination pharmacologic treatment of patients with gout who do not achieve the target serum urate level with monotherapy
- Summarize the latest evidence related to complications associated with gout
- Incorporate evidence-based research into clinical practice
Activity Description
OVERVIEW
Dr. Brian Mandell and Dr. Naomi Schlesinger discuss recent published evidence
related to gout, as well as study results presented at the American College
of Rheumatology Convergence 2020 virtual annual meeting. Dr. Schlesinger
begins with an introduction to this CME activity by touching on a recent
published systematic review indicating that the manifestations of gout extend
beyond the joints, affecting other organs and tissues. Dr. Schlesinger also
provides an overview of some of the challenges encountered in clinical
practice with the use of urate-lowering therapy. In module 1, Dr. Schlesinger
focuses on 2 abstracts presented at ACR Convergence 2020 concerning
gout-related comorbidities, particularly cardiovascular disease. In module 2,
Dr. Mandell focuses on 2 abstracts related to the safety and use of
urate-lowering therapy, specifically allopurinol, febuxostat, and
pegloticase. In module 3, Dr. Mandell discusses 2 abstracts related to the
systemic nature of gout; 1 abstract focuses on heart failure, while the other
focuses on the lumbar spine.
CONTENT AREAS
- Systemic burden of gout
- Gout comorbidities
- Allopurinol
- Febuxostat
- Pegloticase
Statement of Educational Need
- Increased understanding of the safety and efficacy of combination treatment with medications with different mechanisms for lowering the serum urate level
- Increased understanding of updated recommendations regarding the use of combination urate-lowering therapy
- Increased understanding of the association of gout with systemic complications involving the heart, kidneys, and other organs
Agenda
Modules will be structured and recorded in a manner that best supports the nature of the data published by each study. In general, this structure will be:
- Faculty welcomes the learner, introduces the study, states why the study was included in this program [1 min]
- Faculty reviews study methodology [1 min]
- For emphasis or clarity, charts, graphs, or PowerPoint slides may be edited into the final video
- Faculty summarizes key findings [3-4 min]
- How the data advances the current treatment landscape/paradigms
- How the data should be positioned among ongoing research
- How the data connects with current research imperatives
- Clinical significance/implications for current knowledge or practice
- Data one might be expected from the trial in the future
- Faculty provides commentary [5-8 min]
Note: this structure may vary slightly when two smaller studies or abstracts are presented in the same module.
Faculty
Professor of Medicine
Chairman of Academic Medicine
Cleveland Clinic
Cleveland, Ohio
Professor of Medicine
Chief, Division of Rheumatology
UMDNJ-Robert Wood Johnson Medical School
New Brunswick, New Jersey
Conflict of Interest Policy/Disclosure Statement
It is the policy of the Annenberg Center for Health Sciences to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty and planners participating in sponsored programs are expected to identify and reference off-label product use and disclose any relationship with those supporting the activity or any others with products or services available within the scope of the topic being discussed in the educational presentation.
The Annenberg Center for Health Sciences assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE/CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CE/CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.
In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center for Health Sciences policy, the following disclosures have been made:
Faculty
Brian Mandell, MD, PhD
Consultant: Horizon
Data Monitoring Safety Board: Horizon
Speakers Bureau: Genentech
Naomi Schlesinger, MD
Advisory Board: IFM, Johnson and Johnson
Research Support: Amgen, Pfizer
Speakers Bureau: Horizon
Accreditation Statement
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
This activity is an online enduring material. Successful completion is achieved by reading and/or viewing the materials, reflecting on its implications in your practice, and completing the assessment component.
The estimated time to complete the activity is 1.0 hour.
Statement of Commercial Support
This activity is supported by an educational grant from Horizon Therapeutics.
Disclaimer Statement/Disclosure of Unlabeled Use
The faculty for this activity have disclosed that there will be no discussion about the use of products for non-FDA approved applications.
Additional content planners
The following have no significant relationship to disclose:
Greg Scott, PharmD (Medical writer)
Eugene Cullen, MD (Peer Reviewer)
Annenberg Center for Health Sciences
Staff at the Annenberg Center for Health Sciences at Eisenhower have no
relevant commercial relationships to disclose.
The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient’s unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.
Contact Information for Questions About the Activity
For help or questions about this activity please contact Continuing
Education:
ce@annenberg.net
Annenberg Center for Health Sciences
39000 Bob Hope Drive
Dinah Shore Building
Rancho Mirage, CA 92270
Phone 760-773-4500
Fax 760-773-4513
8 AM – 5 PM, Pacific Time, Monday – Friday
From Critique to Consensus: Quantifying and Clarifying Expert Perspectives on the Future Management of Alzheimer’s Disease (AD) – Part 3: Tools for Diagnostic and Monitoring Strategies in the Future Management of AD
StartActivity Details
Expires: February 4, 2022
Accredited By
Target Audience
This activity is intended for neurologists, psychiatrists, and other clinicians involved in the care of patients with AD.
Learning Objectives
Recognize the role of existing and emerging biomarkers in the categorization and monitoring of AD and use this information to identify how this could be implemented in future AD management should such tools become more accessible.
Activity Description
In November of 2020, 26 renowned AD specialists completed a questionnaire documenting their perspectives on several of the most deeply debated and evolving issues in the field. In this activity, three of these experts discuss opinions of those surveyed as well as their own on each of these highly contested topics such as the most prominent drivers of AD and the potential role of amyloid-targeting agents. Using video- and text-based elements, this intervention is designed to not only keep knowledge up to date but also prepare learners for a potential paradigm shift in the way AD is managed in the clinic. Part 3 will focus on the role of biomarkers in AD diagnosis and monitoring as well as the expanded need for these methods should a disease-specific therapy be approved.
Statement of Educational Need
AD is a unique condition in that it is widely researched with substantial representation in the literature, and yet still so much remains unknown or without consensus. With the field at a tipping point of biomarker and therapeutic developments, this activity attempts to provide neurologists, psychiatrists and other dementia clinicians with education that is both relevant and forward thinking. Should the field continue to evolve in the projected manner, these practitioners will need to be prepared for the multitude of considerations that will become relevant to contemporary practice.
Agenda
In the third of this three-part series, Drs. Sabbagh, Smith, and Isaacson will outline the biomarkers that they currently use in AD management alongside their projected changes to standard clinical practices should disease-specific therapies become available. They will also discuss the emergence of novel serum biomarker tests and the potential importance they may develop in the coming years.
Faculty
Director, Lou Ruvo Center for Brain Health
Cleveland Clinic
Las Vegas, Nevada
DR. SABBAGH reported the following financial relationships:
ROYALTY: Harper Collins
CONSULTING FEES: Acadia Pharmaceuticals Inc., Alzheon, Biogen Inc., Cortexyme Inc., Danone, Genentech/Roche, Neurotrope Inc., Stage 2 Innovations
CONTRACTED RESEARCH: Keep Memory Alive Foundation, National Institutes of Health
FEES FOR NON-CME/CE SERVICES: Health and Wellness Partners, Joyce Knapp Communications
OWNERSHIP INTEREST (<5%): Athira, Brain Health Inc., Optimal Cognitive Health Co., NeuroTau Inc., NeuroReserve Inc., uMethod Health Inc., Versanum Inc.
Director, Clinical Research at Byrd Alzheimer’s Institute
University of South Florida
Tampa, Florida
DR. SMITH reported the following financial relationships:
CONTRACTED RESEARCH: AbbVie Inc., Biogen Inc., Biohaven Pharmaceuticals Inc., Eisai, Janssen Pharmaceuticals Inc., Lilly, NeuroEM Therapeutics Inc., Novartis
Director, Alzheimer’s Prevention Clinic
Weill Cornell Medical College/New York Presbyterian Hospital
New York, New York
DR. ISAACSON reported no financial relationships.
Conflict of Interest Policy/Disclosure Statement
Conflict of Interest Disclosure Policy
PIM requires instructors, planners, managers, and other individuals who are
in a position to control the content of this activity to disclose any real or
apparent conflict of interest (COI) they may have as related to the content
of this activity. All identified COI are thoroughly vetted and resolved
according to PIM policy. PIM is committed to providing its learners with high
quality activities and related materials that promote improvements or quality
in healthcare and not a specific proprietary business interest of a
commercial interest.
Planners' and Managers' Disclosure
PIM planners and managers have nothing to disclose. Efficient LLC planners
and managers have nothing to disclose.
Accreditation Statement
In support of improving patient care,
this activity has been planned and implemented by the Postgraduate Institute
for Medicine (PIM) and Efficient LLC. Postgraduate Institute for Medicine is
jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), to provide continuing education for the healthcare
team.
Designation of Credit
PIM designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
In order to receive CME credits, participants must complete the pre- and post-assessment questions, and program evaluation. Certificates will be distributed online at the conclusion of the activity.
For information about the accreditation of this program, please contact Postgraduate Institute for Medicine (www.pimed.com) at 1-800-423-3576 or email to inquiries@pimed.com.
Statement of Commercial Support
This activity is supported by an educational grant from Biogen.
Disclaimer Statement/Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Contact Information for Questions About the Activity
For any questions about this activity, feel free to email us at contact@efficientcme.com.
Activity Details
Expires: February 4, 2022
Accredited By
Target Audience
This activity is intended for neurologists, psychiatrists, and other clinicians involved in the care of patients with AD.
Learning Objectives
Recognize the role of existing and emerging biomarkers in the categorization and monitoring of AD and use this information to identify how this could be implemented in future AD management should such tools become more accessible.
Activity Description
In November of 2020, 26 renowned AD specialists completed a questionnaire documenting their perspectives on several of the most deeply debated and evolving issues in the field. In this activity, three of these experts discuss opinions of those surveyed as well as their own on each of these highly contested topics such as the most prominent drivers of AD and the potential role of amyloid-targeting agents. Using video- and text-based elements, this intervention is designed to not only keep knowledge up to date but also prepare learners for a potential paradigm shift in the way AD is managed in the clinic. Part 3 will focus on the role of biomarkers in AD diagnosis and monitoring as well as the expanded need for these methods should a disease-specific therapy be approved.
Statement of Educational Need
AD is a unique condition in that it is widely researched with substantial representation in the literature, and yet still so much remains unknown or without consensus. With the field at a tipping point of biomarker and therapeutic developments, this activity attempts to provide neurologists, psychiatrists and other dementia clinicians with education that is both relevant and forward thinking. Should the field continue to evolve in the projected manner, these practitioners will need to be prepared for the multitude of considerations that will become relevant to contemporary practice.
Agenda
In the third of this three-part series, Drs. Sabbagh, Smith, and Isaacson will outline the biomarkers that they currently use in AD management alongside their projected changes to standard clinical practices should disease-specific therapies become available. They will also discuss the emergence of novel serum biomarker tests and the potential importance they may develop in the coming years.
Faculty
Director, Lou Ruvo Center for Brain Health
Cleveland Clinic
Las Vegas, Nevada
DR. SABBAGH reported the following financial relationships:
ROYALTY: Harper Collins
CONSULTING FEES: Acadia Pharmaceuticals Inc., Alzheon, Biogen Inc., Cortexyme Inc., Danone, Genentech/Roche, Neurotrope Inc., Stage 2 Innovations
CONTRACTED RESEARCH: Keep Memory Alive Foundation, National Institutes of Health
FEES FOR NON-CME/CE SERVICES: Health and Wellness Partners, Joyce Knapp Communications
OWNERSHIP INTEREST (<5%): Athira, Brain Health Inc., Optimal Cognitive Health Co., NeuroTau Inc., NeuroReserve Inc., uMethod Health Inc., Versanum Inc.
Director, Clinical Research at Byrd Alzheimer’s Institute
University of South Florida
Tampa, Florida
DR. SMITH reported the following financial relationships:
CONTRACTED RESEARCH: AbbVie Inc., Biogen Inc., Biohaven Pharmaceuticals Inc., Eisai, Janssen Pharmaceuticals Inc., Lilly, NeuroEM Therapeutics Inc., Novartis
Director, Alzheimer’s Prevention Clinic
Weill Cornell Medical College/New York Presbyterian Hospital
New York, New York
DR. ISAACSON reported no financial relationships.
Conflict of Interest Policy/Disclosure Statement
Conflict of Interest Disclosure Policy
PIM requires instructors, planners, managers, and other individuals who are
in a position to control the content of this activity to disclose any real or
apparent conflict of interest (COI) they may have as related to the content
of this activity. All identified COI are thoroughly vetted and resolved
according to PIM policy. PIM is committed to providing its learners with high
quality activities and related materials that promote improvements or quality
in healthcare and not a specific proprietary business interest of a
commercial interest.
Planners' and Managers' Disclosure
PIM planners and managers have nothing to disclose. Efficient LLC planners
and managers have nothing to disclose.
Accreditation Statement
In support of improving patient care,
this activity has been planned and implemented by the Postgraduate Institute
for Medicine (PIM) and Efficient LLC. Postgraduate Institute for Medicine is
jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), to provide continuing education for the healthcare
team.
Designation of Credit
PIM designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
In order to receive CME credits, participants must complete the pre- and post-assessment questions, and program evaluation. Certificates will be distributed online at the conclusion of the activity.
For information about the accreditation of this program, please contact Postgraduate Institute for Medicine (www.pimed.com) at 1-800-423-3576 or email to inquiries@pimed.com.
Statement of Commercial Support
This activity is supported by an educational grant from Biogen.
Disclaimer Statement/Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Contact Information for Questions About the Activity
For any questions about this activity, feel free to email us at contact@efficientcme.com.
From Critique to Consensus: Quantifying and Clarifying Expert Perspectives on the Future Management of Alzheimer’s Disease (AD) – Part 2: Current Treatments and Rising Phase 3 Disease-Modifying Therapies
StartActivity Details
Expires: February 4, 2022
Accredited By
Target Audience
This activity is intended for neurologists, psychiatrists, and other clinicians involved in the care of patients with AD.
Learning Objectives
- Assess patient factors that may affect eligibility for treatment with amyloid-targeted disease modifying therapies (DMTs) to determine for which patients this strategy holds the most promise if approved.
- Evaluate expert opinions of and available Phase 2/3 data with amyloid-targeting DMTs to assess their potential role in future patient management.
Activity Description
In November of 2020, 26 renowned AD specialists completed a questionnaire documenting their perspectives on several of the most deeply debated and evolving issues in the field. In this activity, three of these experts discuss opinions of those surveyed as well as their own on each of these highly contested topics such as the most prominent drivers of AD and the potential role of amyloid-targeting agents. Using video- and text-based elements, this intervention is designed to not only keep knowledge up to date but also prepare learners for a potential paradigm shift in the way AD is managed in the clinic. Part 2 will focus on the treatments currently available for AD contrasted with the rising agents that have the potential to enter the treatment armamentarium in the near future.
Statement of Educational Need
AD is a unique condition in that it is widely researched with substantial representation in the literature, and yet still so much remains unknown or without consensus. With the field at a tipping point of biomarker and therapeutic developments, this activity attempts to provide neurologists, psychiatrists and other dementia clinicians with education that is both relevant and forward thinking. Should the field continue to evolve in the projected manner, these practitioners will need to be prepared for the multitude of considerations that will become relevant to contemporary practice.
Agenda
In the second of this three-part series, Drs. Sabbagh, Smith, and Isaacson will discuss the use and limitations of currently available AD therapies as well as the potential role of rising, disease-specific therapies that are on the horizon.
Faculty
Director, Lou Ruvo Center for Brain Health
Cleveland Clinic
Las Vegas, Nevada
DR. SABBAGH reported the following financial relationships:
ROYALTY: Harper Collins
CONSULTING FEES: Acadia Pharmaceuticals Inc., Alzheon, Biogen Inc., Cortexyme Inc., Danone, Genentech/Roche, Neurotrope Inc., Stage 2 Innovations
CONTRACTED RESEARCH: Keep Memory Alive Foundation, National Institutes of Health
FEES FOR NON-CME/CE SERVICES: Health and Wellness Partners, Joyce Knapp Communications
OWNERSHIP INTEREST (<5%): Athira, Brain Health Inc., Optimal Cognitive Health Co., NeuroTau Inc., NeuroReserve Inc., uMethod Health Inc., Versanum Inc.
Director, Clinical Research at Byrd Alzheimer’s Institute
University of South Florida
Tampa, Florida
DR. SMITH reported the following financial relationships:
CONTRACTED RESEARCH: AbbVie Inc., Biogen Inc., Biohaven Pharmaceuticals Inc., Eisai, Janssen Pharmaceuticals Inc., Lilly, NeuroEM Therapeutics Inc., Novartis
Director, Alzheimer’s Prevention Clinic
Weill Cornell Medical College/New York Presbyterian Hospital
New York, New York
DR. ISAACSON reported no financial relationships.
Conflict of Interest Policy/Disclosure Statement
Conflict of Interest Disclosure Policy
PIM requires instructors, planners, managers, and other individuals who are
in a position to control the content of this activity to disclose any real or
apparent conflict of interest (COI) they may have as related to the content
of this activity. All identified COI are thoroughly vetted and resolved
according to PIM policy. PIM is committed to providing its learners with high
quality activities and related materials that promote improvements or quality
in healthcare and not a specific proprietary business interest of a
commercial interest.
Planners' and Managers' Disclosure
PIM planners and managers have nothing to disclose. Efficient LLC planners
and managers have nothing to disclose.
Accreditation Statement
In support of improving patient care,
this activity has been planned and implemented by the Postgraduate Institute
for Medicine (PIM) and Efficient LLC. Postgraduate Institute for Medicine is
jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), to provide continuing education for the healthcare
team.
Designation of Credit
PIM designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
In order to receive CME credits, participants must complete the pre- and post-assessment questions, and program evaluation. Certificates will be distributed online at the conclusion of the activity.
For information about the accreditation of this program, please contact Postgraduate Institute for Medicine (www.pimed.com) at 1-800-423-3576 or email to inquiries@pimed.com.
Statement of Commercial Support
This activity is supported by an educational grant from Biogen.
Disclaimer Statement/Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Contact Information for Questions About the Activity
For any questions about this activity, feel free to email us at contact@efficientcme.com.
Activity Details
Expires: February 4, 2022
Accredited By
Target Audience
This activity is intended for neurologists, psychiatrists, and other clinicians involved in the care of patients with AD.
Learning Objectives
- Assess patient factors that may affect eligibility for treatment with amyloid-targeted disease modifying therapies (DMTs) to determine for which patients this strategy holds the most promise if approved.
- Evaluate expert opinions of and available Phase 2/3 data with amyloid-targeting DMTs to assess their potential role in future patient management.
Activity Description
In November of 2020, 26 renowned AD specialists completed a questionnaire documenting their perspectives on several of the most deeply debated and evolving issues in the field. In this activity, three of these experts discuss opinions of those surveyed as well as their own on each of these highly contested topics such as the most prominent drivers of AD and the potential role of amyloid-targeting agents. Using video- and text-based elements, this intervention is designed to not only keep knowledge up to date but also prepare learners for a potential paradigm shift in the way AD is managed in the clinic. Part 2 will focus on the treatments currently available for AD contrasted with the rising agents that have the potential to enter the treatment armamentarium in the near future.
Statement of Educational Need
AD is a unique condition in that it is widely researched with substantial representation in the literature, and yet still so much remains unknown or without consensus. With the field at a tipping point of biomarker and therapeutic developments, this activity attempts to provide neurologists, psychiatrists and other dementia clinicians with education that is both relevant and forward thinking. Should the field continue to evolve in the projected manner, these practitioners will need to be prepared for the multitude of considerations that will become relevant to contemporary practice.
Agenda
In the second of this three-part series, Drs. Sabbagh, Smith, and Isaacson will discuss the use and limitations of currently available AD therapies as well as the potential role of rising, disease-specific therapies that are on the horizon.
Faculty
Director, Lou Ruvo Center for Brain Health
Cleveland Clinic
Las Vegas, Nevada
DR. SABBAGH reported the following financial relationships:
ROYALTY: Harper Collins
CONSULTING FEES: Acadia Pharmaceuticals Inc., Alzheon, Biogen Inc., Cortexyme Inc., Danone, Genentech/Roche, Neurotrope Inc., Stage 2 Innovations
CONTRACTED RESEARCH: Keep Memory Alive Foundation, National Institutes of Health
FEES FOR NON-CME/CE SERVICES: Health and Wellness Partners, Joyce Knapp Communications
OWNERSHIP INTEREST (<5%): Athira, Brain Health Inc., Optimal Cognitive Health Co., NeuroTau Inc., NeuroReserve Inc., uMethod Health Inc., Versanum Inc.
Director, Clinical Research at Byrd Alzheimer’s Institute
University of South Florida
Tampa, Florida
DR. SMITH reported the following financial relationships:
CONTRACTED RESEARCH: AbbVie Inc., Biogen Inc., Biohaven Pharmaceuticals Inc., Eisai, Janssen Pharmaceuticals Inc., Lilly, NeuroEM Therapeutics Inc., Novartis
Director, Alzheimer’s Prevention Clinic
Weill Cornell Medical College/New York Presbyterian Hospital
New York, New York
DR. ISAACSON reported no financial relationships.
Conflict of Interest Policy/Disclosure Statement
Conflict of Interest Disclosure Policy
PIM requires instructors, planners, managers, and other individuals who are
in a position to control the content of this activity to disclose any real or
apparent conflict of interest (COI) they may have as related to the content
of this activity. All identified COI are thoroughly vetted and resolved
according to PIM policy. PIM is committed to providing its learners with high
quality activities and related materials that promote improvements or quality
in healthcare and not a specific proprietary business interest of a
commercial interest.
Planners' and Managers' Disclosure
PIM planners and managers have nothing to disclose. Efficient LLC planners
and managers have nothing to disclose.
Accreditation Statement
In support of improving patient care,
this activity has been planned and implemented by the Postgraduate Institute
for Medicine (PIM) and Efficient LLC. Postgraduate Institute for Medicine is
jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), to provide continuing education for the healthcare
team.
Designation of Credit
PIM designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
In order to receive CME credits, participants must complete the pre- and post-assessment questions, and program evaluation. Certificates will be distributed online at the conclusion of the activity.
For information about the accreditation of this program, please contact Postgraduate Institute for Medicine (www.pimed.com) at 1-800-423-3576 or email to inquiries@pimed.com.
Statement of Commercial Support
This activity is supported by an educational grant from Biogen.
Disclaimer Statement/Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Contact Information for Questions About the Activity
For any questions about this activity, feel free to email us at contact@efficientcme.com.
From Critique to Consensus: Quantifying and Clarifying Expert Perspectives on the Future Management of Alzheimer’s Disease (AD) – Part 1: Evolving Understanding of Pathophysiology and Proposed Framework of AD
StartActivity Details
Expires: February 4, 2022
Accredited By
Target Audience
This activity is intended for neurologists, psychiatrists, and other clinicians involved in the care of patients with AD.
Learning Objectives
- Assess the fundamental principles and current status of the amyloid hypothesis—including historical obstacles associated with evaluating amyloid targeting disease modifying therapies (DMTs)—to appraise its potential utility and limitations in guiding AD diagnostic and clinical strategy.
- Identify the potential utility of a biomarker-based approach to AD management in order to understand how such strategies may be integrated into practice in the event that targeted therapies become available.
Activity Description
In November of 2020, 26 renowned AD specialists completed a questionnaire documenting their perspectives on several of the most deeply debated and evolving issues in the field. In this activity, three of these experts discuss opinions of those surveyed as well as their own on each of these highly contested topics such as the most prominent drivers of AD and the potential role of amyloid-targeting agents. Using video- and text-based elements, this intervention is designed to not only keep knowledge up to date but also prepare learners for a potential paradigm shift in the way AD is managed in the clinic. Part 1 will focus on the way our understanding of AD pathophysiology has evolved and the most widely held viewpoints among modern dementia specialists.
Statement of Educational Need
AD is a unique condition in that it is widely researched with substantial representation in the literature, and yet still so much remains unknown or without consensus. With the field at a tipping point of biomarker and therapeutic developments, this activity attempts to provide neurologists, psychiatrists and other dementia clinicians with education that is both relevant and forward thinking. Should the field continue to evolve in the projected manner, these practitioners will need to be prepared for the multitude of considerations that will become relevant to contemporary practice.
Agenda
In the first of this three-part series, Drs. Sabbagh, Smith, and Isaacson will review the traditional theories of the path to AD as well as their own personal takes on modern advancements in its understanding. They will also discuss how the historical mystery of AD has contributed to the widespread failures in pharmaceutical development and why these failures may provide more insight than may be apparent at the surface.
Faculty
Director, Lou Ruvo Center for Brain Health
Cleveland Clinic
Las Vegas, Nevada
DR. SABBAGH reported the following financial relationships:
ROYALTY: Harper Collins
CONSULTING FEES: Acadia Pharmaceuticals Inc., Alzheon, Biogen Inc., Cortexyme Inc., Danone, Genentech/Roche, Neurotrope Inc., Stage 2 Innovations
CONTRACTED RESEARCH: Keep Memory Alive Foundation, National Institutes of Health
FEES FOR NON-CME/CE SERVICES: Health and Wellness Partners, Joyce Knapp Communications
OWNERSHIP INTEREST (<5%): Athira, Brain Health Inc., Optimal Cognitive Health Co., NeuroTau Inc., NeuroReserve Inc., uMethod Health Inc., Versanum Inc.
Director, Clinical Research at Byrd Alzheimer’s Institute
University of South Florida
Tampa, Florida
DR. SMITH reported the following financial relationships:
CONTRACTED RESEARCH: AbbVie Inc., Biogen Inc., Biohaven Pharmaceuticals Inc., Eisai, Janssen Pharmaceuticals Inc., Lilly, NeuroEM Therapeutics Inc., Novartis
Director, Alzheimer’s Prevention Clinic
Weill Cornell Medical College/New York Presbyterian Hospital
New York, New York
DR. ISAACSON reported no financial relationships.
Conflict of Interest Policy/Disclosure Statement
Conflict of Interest Disclosure Policy
PIM requires instructors, planners, managers, and other individuals who are
in a position to control the content of this activity to disclose any real or
apparent conflict of interest (COI) they may have as related to the content
of this activity. All identified COI are thoroughly vetted and resolved
according to PIM policy. PIM is committed to providing its learners with high
quality activities and related materials that promote improvements or quality
in healthcare and not a specific proprietary business interest of a
commercial interest.
Planners' and Managers' Disclosure
PIM planners and managers have nothing to disclose. Efficient LLC planners
and managers have nothing to disclose.
Accreditation Statement
In support of improving patient care,
this activity has been planned and implemented by the Postgraduate Institute
for Medicine (PIM) and Efficient LLC. Postgraduate Institute for Medicine is
jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), to provide continuing education for the healthcare
team.
Designation of Credit
PIM designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
In order to receive CME credits, participants must complete the pre- and post-assessment questions, and program evaluation. Certificates will be distributed online at the conclusion of the activity.
For information about the accreditation of this program, please contact Postgraduate Institute for Medicine (www.pimed.com) at 1-800-423-3576 or email to inquiries@pimed.com.
Statement of Commercial Support
This activity is supported by an educational grant from Biogen.
Disclaimer Statement/Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Contact Information for Questions About the Activity
For any questions about this activity, feel free to email us at contact@efficientcme.com.
Activity Details
Expires: February 4, 2022
Accredited By
Target Audience
This activity is intended for neurologists, psychiatrists, and other clinicians involved in the care of patients with AD.
Learning Objectives
- Assess the fundamental principles and current status of the amyloid hypothesis—including historical obstacles associated with evaluating amyloid targeting disease modifying therapies (DMTs)—to appraise its potential utility and limitations in guiding AD diagnostic and clinical strategy.
- Identify the potential utility of a biomarker-based approach to AD management in order to understand how such strategies may be integrated into practice in the event that targeted therapies become available.
Activity Description
In November of 2020, 26 renowned AD specialists completed a questionnaire documenting their perspectives on several of the most deeply debated and evolving issues in the field. In this activity, three of these experts discuss opinions of those surveyed as well as their own on each of these highly contested topics such as the most prominent drivers of AD and the potential role of amyloid-targeting agents. Using video- and text-based elements, this intervention is designed to not only keep knowledge up to date but also prepare learners for a potential paradigm shift in the way AD is managed in the clinic. Part 1 will focus on the way our understanding of AD pathophysiology has evolved and the most widely held viewpoints among modern dementia specialists.
Statement of Educational Need
AD is a unique condition in that it is widely researched with substantial representation in the literature, and yet still so much remains unknown or without consensus. With the field at a tipping point of biomarker and therapeutic developments, this activity attempts to provide neurologists, psychiatrists and other dementia clinicians with education that is both relevant and forward thinking. Should the field continue to evolve in the projected manner, these practitioners will need to be prepared for the multitude of considerations that will become relevant to contemporary practice.
Agenda
In the first of this three-part series, Drs. Sabbagh, Smith, and Isaacson will review the traditional theories of the path to AD as well as their own personal takes on modern advancements in its understanding. They will also discuss how the historical mystery of AD has contributed to the widespread failures in pharmaceutical development and why these failures may provide more insight than may be apparent at the surface.
Faculty
Director, Lou Ruvo Center for Brain Health
Cleveland Clinic
Las Vegas, Nevada
DR. SABBAGH reported the following financial relationships:
ROYALTY: Harper Collins
CONSULTING FEES: Acadia Pharmaceuticals Inc., Alzheon, Biogen Inc., Cortexyme Inc., Danone, Genentech/Roche, Neurotrope Inc., Stage 2 Innovations
CONTRACTED RESEARCH: Keep Memory Alive Foundation, National Institutes of Health
FEES FOR NON-CME/CE SERVICES: Health and Wellness Partners, Joyce Knapp Communications
OWNERSHIP INTEREST (<5%): Athira, Brain Health Inc., Optimal Cognitive Health Co., NeuroTau Inc., NeuroReserve Inc., uMethod Health Inc., Versanum Inc.
Director, Clinical Research at Byrd Alzheimer’s Institute
University of South Florida
Tampa, Florida
DR. SMITH reported the following financial relationships:
CONTRACTED RESEARCH: AbbVie Inc., Biogen Inc., Biohaven Pharmaceuticals Inc., Eisai, Janssen Pharmaceuticals Inc., Lilly, NeuroEM Therapeutics Inc., Novartis
Director, Alzheimer’s Prevention Clinic
Weill Cornell Medical College/New York Presbyterian Hospital
New York, New York
DR. ISAACSON reported no financial relationships.
Conflict of Interest Policy/Disclosure Statement
Conflict of Interest Disclosure Policy
PIM requires instructors, planners, managers, and other individuals who are
in a position to control the content of this activity to disclose any real or
apparent conflict of interest (COI) they may have as related to the content
of this activity. All identified COI are thoroughly vetted and resolved
according to PIM policy. PIM is committed to providing its learners with high
quality activities and related materials that promote improvements or quality
in healthcare and not a specific proprietary business interest of a
commercial interest.
Planners' and Managers' Disclosure
PIM planners and managers have nothing to disclose. Efficient LLC planners
and managers have nothing to disclose.
Accreditation Statement
In support of improving patient care,
this activity has been planned and implemented by the Postgraduate Institute
for Medicine (PIM) and Efficient LLC. Postgraduate Institute for Medicine is
jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), to provide continuing education for the healthcare
team.
Designation of Credit
PIM designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
In order to receive CME credits, participants must complete the pre- and post-assessment questions, and program evaluation. Certificates will be distributed online at the conclusion of the activity.
For information about the accreditation of this program, please contact Postgraduate Institute for Medicine (www.pimed.com) at 1-800-423-3576 or email to inquiries@pimed.com.
Statement of Commercial Support
This activity is supported by an educational grant from Biogen.
Disclaimer Statement/Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Contact Information for Questions About the Activity
For any questions about this activity, feel free to email us at contact@efficientcme.com.
What's New in Systemic Lupus Erythematosus? Unlocking Novel Paths to Patient Care
StartActivity Details
2.0 Contact Hour(s)
Expires: January 30, 2022
Provided By
This activity is jointly provided by Postgraduate Institute for Medicine and Integritas Communications.
Target Audience
This activity is intended for rheumatologists and other specialists involved in the management of patients with systemic lupus erythematosus (SLE).
Learning Objectives
Upon completion of this activity, the participant should be better able to:
- Describe SLE pathophysiology with a focus on novel treatment targets
- Evaluate patients with SLE using evidence-based classification criteria and measures of disease activity
- Discuss new clinical trial data and regulatory status for current and emerging targeted therapies in moderate-to-severe SLE
- Manage patients with moderate-to-severe SLE based on a treat-to-target approach, evolving clinical evidence, unresolved symptoms, and patient preferences
Activity Description
Despite improved understanding of pathophysiologic mechanisms, additional assessment strategies, and hope for more available treatments, specialists face challenges in managing the diverse manifestations of, and patient populations with, SLE. During this Engaging the Patient™ enduring activity, a panel of 3 experts in SLE share interpretive insights on SLE pathophysiology, diagnosis, the use of classification criteria and measures of disease activity, and recent clinical trial data for newer targeted therapies. This forward-looking CME program aims to capture expert interpretations of existing and evolving evidence to help rheumatologists provide care that minimizes recurrent disease activity flares and cumulative organ damage that are key factors in long-term outcomes.
Agenda
- How Do We Evaluate Patients with Suspected SLE?
- Comprehensive Treatment of SLE: Where are We Now?
- Insights into SLE Pathophysiology
- Linking Pathophysiology to Targets for Drug Development
- Patient Goals, Treat-to-Target, and Treatment Success
- Faculty Closing Comments
- Ask the Experts Q&A Session
Faculty
Chief of Rheumatology
Northwell Health
Professor
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Great Neck, New York
Consulting Fees: Alexion Pharmaceuticals Inc., Amgen Inc., AstraZeneca, Biogen, Bristol Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo Company, Limited, Eli Lilly and Company, EMD Serono, Equillium, Inc., Galapagos NV, Genentech, GlaxoSmithKline plc., Janssen Pharmaceuticals, Inc., Kezar Life Sciences, Inc., MorphoSys AG, Novartis International AG, Reistone Biopharma, Sanofi S.A., Takeda Pharmaceutical Company Limited, UCB; Contracted Research/Investigator: Amgen Inc., AstraZeneca, Biogen, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly and Company, EMD Serono, Equillium, Inc., Genentech, GlaxoSmithKline plc., Kezar Life Sciences, Inc., Nektar Therapeutics, Takeda Pharmaceutical Company Limited, UCB; Other (Committee Member): Lupus Research Alliance, The Lupus Academy
Associate Professor of Medicine
Harvard Medical School
Director of Clinical Lupus Trials
Division of Rheumatology
Vice Chair of Clinical Affairs
Department of Medicine
Brigham and Women's Hospital
Boston, Massachusetts
Royalties: UpToDate; Consulting Fees: Amgen Inc., EMD Serono, Kezar Life Sciences, Inc.; Contracted Research: Bristol Myers Squibb, Sanofi S.A.
Professor of Medicine
Department of Medicine
Head, Rheumatic Disease Group
Monash Centre for Inflammatory Diseases
Monash University (Australia)
Melbourne, Australia
Consulting Fees: AbbVie, Amgen Inc., AstraZeneca, Biogen, Bristol Myers Squibb, GlaxoSmithKline plc., UCB; Fees for Non-CME/CE Services Received Directly from a Commercial Interest or Their Agents: Sanofi, Novartis; Contracted Research: AstraZeneca, Bristol Myers Squibb, Eli Lilly and Company, EMD Serono, Janssen Pharmaceuticals, Inc.
Joint Accreditation Statement
In support of improving
patient care, this activity has been planned and implemented by the
Postgraduate Institute for Medicine (PIM) and Integritas Communications. PIM
is jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the health care team.
Physician Continuing Medical Education
PIM designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 2.0 contact hours. Designated for 0.75 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
Disclosure of Conflicts of Interest
PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.
Planners and Managers: The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.
Instructions to Receive Credit
In order to receive credit, participants must complete the preactivity questionnaire, posttest, and program evaluation. Participants must also score a 75% on the posttest.
Statement of Commercial Support
This activity is supported by an independent educational grant from AstraZeneca.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Contact Information for Questions About the Activity
PIM Contact Information
For information about the accreditation of this program, please contact PIM
via email at inquiries@pimed.com or at http://www.pimed.com.
Integritas Contact Information
For all other questions regarding this activity, please contact Christa
Master with Integritas Communications via email at
cmaster@integritasgrp.com.
Activity Details
2.0 Contact Hour(s)
Expires: January 30, 2022
Provided By
This activity is jointly provided by Postgraduate Institute for Medicine and Integritas Communications.
Target Audience
This activity is intended for rheumatologists and other specialists involved in the management of patients with systemic lupus erythematosus (SLE).
Learning Objectives
Upon completion of this activity, the participant should be better able to:
- Describe SLE pathophysiology with a focus on novel treatment targets
- Evaluate patients with SLE using evidence-based classification criteria and measures of disease activity
- Discuss new clinical trial data and regulatory status for current and emerging targeted therapies in moderate-to-severe SLE
- Manage patients with moderate-to-severe SLE based on a treat-to-target approach, evolving clinical evidence, unresolved symptoms, and patient preferences
Activity Description
Despite improved understanding of pathophysiologic mechanisms, additional assessment strategies, and hope for more available treatments, specialists face challenges in managing the diverse manifestations of, and patient populations with, SLE. During this Engaging the Patient™ enduring activity, a panel of 3 experts in SLE share interpretive insights on SLE pathophysiology, diagnosis, the use of classification criteria and measures of disease activity, and recent clinical trial data for newer targeted therapies. This forward-looking CME program aims to capture expert interpretations of existing and evolving evidence to help rheumatologists provide care that minimizes recurrent disease activity flares and cumulative organ damage that are key factors in long-term outcomes.
Agenda
- How Do We Evaluate Patients with Suspected SLE?
- Comprehensive Treatment of SLE: Where are We Now?
- Insights into SLE Pathophysiology
- Linking Pathophysiology to Targets for Drug Development
- Patient Goals, Treat-to-Target, and Treatment Success
- Faculty Closing Comments
- Ask the Experts Q&A Session
Faculty
Chief of Rheumatology
Northwell Health
Professor
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Great Neck, New York
Consulting Fees: Alexion Pharmaceuticals Inc., Amgen Inc., AstraZeneca, Biogen, Bristol Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo Company, Limited, Eli Lilly and Company, EMD Serono, Equillium, Inc., Galapagos NV, Genentech, GlaxoSmithKline plc., Janssen Pharmaceuticals, Inc., Kezar Life Sciences, Inc., MorphoSys AG, Novartis International AG, Reistone Biopharma, Sanofi S.A., Takeda Pharmaceutical Company Limited, UCB; Contracted Research/Investigator: Amgen Inc., AstraZeneca, Biogen, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly and Company, EMD Serono, Equillium, Inc., Genentech, GlaxoSmithKline plc., Kezar Life Sciences, Inc., Nektar Therapeutics, Takeda Pharmaceutical Company Limited, UCB; Other (Committee Member): Lupus Research Alliance, The Lupus Academy
Associate Professor of Medicine
Harvard Medical School
Director of Clinical Lupus Trials
Division of Rheumatology
Vice Chair of Clinical Affairs
Department of Medicine
Brigham and Women's Hospital
Boston, Massachusetts
Royalties: UpToDate; Consulting Fees: Amgen Inc., EMD Serono, Kezar Life Sciences, Inc.; Contracted Research: Bristol Myers Squibb, Sanofi S.A.
Professor of Medicine
Department of Medicine
Head, Rheumatic Disease Group
Monash Centre for Inflammatory Diseases
Monash University (Australia)
Melbourne, Australia
Consulting Fees: AbbVie, Amgen Inc., AstraZeneca, Biogen, Bristol Myers Squibb, GlaxoSmithKline plc., UCB; Fees for Non-CME/CE Services Received Directly from a Commercial Interest or Their Agents: Sanofi, Novartis; Contracted Research: AstraZeneca, Bristol Myers Squibb, Eli Lilly and Company, EMD Serono, Janssen Pharmaceuticals, Inc.
Joint Accreditation Statement
In support of improving
patient care, this activity has been planned and implemented by the
Postgraduate Institute for Medicine (PIM) and Integritas Communications. PIM
is jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the health care team.
Physician Continuing Medical Education
PIM designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 2.0 contact hours. Designated for 0.75 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
Disclosure of Conflicts of Interest
PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.
Planners and Managers: The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.
Instructions to Receive Credit
In order to receive credit, participants must complete the preactivity questionnaire, posttest, and program evaluation. Participants must also score a 75% on the posttest.
Statement of Commercial Support
This activity is supported by an independent educational grant from AstraZeneca.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Contact Information for Questions About the Activity
PIM Contact Information
For information about the accreditation of this program, please contact PIM
via email at inquiries@pimed.com or at http://www.pimed.com.
Integritas Contact Information
For all other questions regarding this activity, please contact Christa
Master with Integritas Communications via email at
cmaster@integritasgrp.com.
Calcitropes, Myotropes, and Mitotropes: The Role of Emerging Therapies to Improve Systolic Function in HFrEF
StartCalcitropes, Myotropes, and Mitotropes: The Role of Emerging Therapies to Improve Systolic Function in HFrEF
Activity Details
Expires: TBD
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is cardiologists and other health care professionals involved in the management of patients with heart failure with reduced ejection fraction (HFrEF).
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Describe the benefits and pitfalls of traditional inotropic agents and their impact on long-term outcomes in the treatment of HFrEF.
- Evaluate new terminology with mechanistic nomenclature to foster effective communication and highlight novel therapeutic agents to improve myocardial contractility and function.
- Assess the unique mechanisms of action of cardiac myotropes and clinical evidence regarding their safety and efficacy in the treatment of HFrEF.
Activity Description
Reductions in myocardial contractile function and increases in cardiac wall stress can trigger multiple interrelated compensatory mechanisms, including neurohormonal activation and ventricular remodeling. These result in increased myocardial oxygen demand and reduced contractile efficiency, promoting additional myocardial injury and cardiomyocyte death. These effects perpetuate a negative feedback cycle that results in symptomatic heart failure with a reduced ejection fraction (HFrEF) and, eventually, death.
Multiple lifesaving therapies, including angiotensin converting enzyme inhibitors; angiotensin receptor blockers; mineralocorticoid antagonists; beta blockers; and, most recently, dual-acting angiotensin receptor-neprilysin inhibitors, have been developed to address the neurohormonal activation in HFrEF. However, these therapies do not directly address the central driver in the pathogenesis of HFrEF—decreased myocardial contractility—resulting in decrease systolic function. The use of conventional inotropic agents may increase morbidity as well as mortality and are associated with a higher risk of ventricular arrhythmia, atrial fibrillation, hypotension, induced myocardial ischemia, increased myocardial oxygen consumption, and direct myocyte toxicity due to an intracellular calcium overload.
Pharmacologic agents that improve myocardial performance can be classified as calcitropes that alter intracellular calcium concentrations, myotropes that affect the molecular motor and scaffolding, and mitotropes that influence the myocardial energetics. In this educational activity, faculty will discuss the latest data regarding newer agents in development that can directly enhance myocardial contractility, without increasing cardiac workload or oxygen consumption.
Agenda
Matters of the Heart: Unmet Needs in Heart Failure With Reduced Ejection Fraction (HFrEF)
Emerging HFrEF Therapies: A Look at the Clinical Evidence
Activity Chair
Professor of Medicine, University of California San Francisco
Director, Heart Failure Program
Director, Echocardiography
San Francisco VA Medical Center
San Francisco, CA
Consulting Fee: Abbott Medical Optics, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cytokinetics, Medtronic, Merck, Novartis
Contracted Research: Abbott Medical Optics, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cytokinetics, Medtronic, Novartis
Faculty
Director, Infiltrative Cardiomyopathy Center
Associate Director, Heart Failure Research
Inova Heart and Vascular Institute
Falls Church, VA
Consulting Fee: Amgen, Cytokinetics, Windtree
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Cytokinetics, Inc.
Disclaimer
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA–approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Calcitropes, Myotropes, and Mitotropes: The Role of Emerging Therapies to Improve Systolic Function in HFrEF
Activity Details
Expires: TBD
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is cardiologists and other health care professionals involved in the management of patients with heart failure with reduced ejection fraction (HFrEF).
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Describe the benefits and pitfalls of traditional inotropic agents and their impact on long-term outcomes in the treatment of HFrEF.
- Evaluate new terminology with mechanistic nomenclature to foster effective communication and highlight novel therapeutic agents to improve myocardial contractility and function.
- Assess the unique mechanisms of action of cardiac myotropes and clinical evidence regarding their safety and efficacy in the treatment of HFrEF.
Activity Description
Reductions in myocardial contractile function and increases in cardiac wall stress can trigger multiple interrelated compensatory mechanisms, including neurohormonal activation and ventricular remodeling. These result in increased myocardial oxygen demand and reduced contractile efficiency, promoting additional myocardial injury and cardiomyocyte death. These effects perpetuate a negative feedback cycle that results in symptomatic heart failure with a reduced ejection fraction (HFrEF) and, eventually, death.
Multiple lifesaving therapies, including angiotensin converting enzyme inhibitors; angiotensin receptor blockers; mineralocorticoid antagonists; beta blockers; and, most recently, dual-acting angiotensin receptor-neprilysin inhibitors, have been developed to address the neurohormonal activation in HFrEF. However, these therapies do not directly address the central driver in the pathogenesis of HFrEF—decreased myocardial contractility—resulting in decrease systolic function. The use of conventional inotropic agents may increase morbidity as well as mortality and are associated with a higher risk of ventricular arrhythmia, atrial fibrillation, hypotension, induced myocardial ischemia, increased myocardial oxygen consumption, and direct myocyte toxicity due to an intracellular calcium overload.
Pharmacologic agents that improve myocardial performance can be classified as calcitropes that alter intracellular calcium concentrations, myotropes that affect the molecular motor and scaffolding, and mitotropes that influence the myocardial energetics. In this educational activity, faculty will discuss the latest data regarding newer agents in development that can directly enhance myocardial contractility, without increasing cardiac workload or oxygen consumption.
Agenda
Matters of the Heart: Unmet Needs in Heart Failure With Reduced Ejection Fraction (HFrEF)
Emerging HFrEF Therapies: A Look at the Clinical Evidence
Activity Chair
Professor of Medicine, University of California San Francisco
Director, Heart Failure Program
Director, Echocardiography
San Francisco VA Medical Center
San Francisco, CA
Consulting Fee: Abbott Medical Optics, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cytokinetics, Medtronic, Merck, Novartis
Contracted Research: Abbott Medical Optics, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cytokinetics, Medtronic, Novartis
Faculty
Director, Infiltrative Cardiomyopathy Center
Associate Director, Heart Failure Research
Inova Heart and Vascular Institute
Falls Church, VA
Consulting Fee: Amgen, Cytokinetics, Windtree
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Cytokinetics, Inc.
Disclaimer
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA–approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Incorporating Influenza Treatment Paradigms that Reduce Complications: A Wheel of Knowledge Challenge
StartActivity Details
ABIM/AAFP/AANP/AAPA
Expires: January 14, 2022
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is family practice physicians, internists, pediatricians, physician assistants, nurse practitioners, and other health care professionals involved in the management of patients with influenza.
Learning Objectives
Upon successful completion of this educational activity, participants should be better able to:
- Diagnose patients with influenza infection by using guideline recommendations and best practices.
- Distinguish antiviral treatments for influenza based on their efficacy, safety, and ability to reduce viral shedding.
- Select the most appropriate treatment for patients diagnosed with influenza who are at normal or high risk for complications.
- Assess the use of antiviral prophylaxis in people who have been exposed to influenza infection.
Activity Description
While the impact of influenza varies, it places a substantial burden on the health of people in the United States each year. The Centers for Disease Control and Prevention (CDC) estimates that influenza has resulted in between 9.2 million and 35.6 million illnesses, between 140,000 and 710,000 hospitalizations, and between 12,000 and 56,000 deaths annually since 2010. There is a need for better treatments for patients with influenza infection, preventative measures, and better mitigation for the impact associated with a pandemic. Antivirals with different targets as well as different mechanisms of action provide multiple therapeutic options, and hold promise in improving treatment effectiveness. Family physicians and advanced practice clinicians are integral for the expedient management of patients with flu. In this Wheel of Knowledge Challenge, your knowledge will be tested on the latest updates in diagnosing and managing influenza.
Activity Chair
Clinical Professor of Family and Community Medicine
Sidney Kimmel Medical College
Thomas Jefferson University
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA
Disclosure
Consulting Fee: Bayer, GlaxoSmithKline, Sanofi Pasteur
Speakers Bureau: Sanofi Pasteur
Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.
Linda A. Giarraputo, PA-C
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of
this CME activity enables the participant to earn up to 0.50 Medical
Knowledge MOC points in the American Board of Internal Medicine’s (ABIM)
Maintenance of Certification (MOC) program. It is the CME activity provider’s
responsibility to submit participant completion information to ACCME for the
purpose of granting ABIM MOC credit.
Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.
The AAFP has reviewed
Incorporating Influenza Treatment Paradigms that Reduce Complications: A
Wheel of Knowledge Challenge and deemed it acceptable for up to 0.50 Enduring
Materials, Self-Study AAFP Prescribed credit. Term of Approval is from
1/15/2021 to 1/14/2022. Physicians should claim only the credit commensurate
with the extent of their participation in the activity.
This activity has been
reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria.
This activity is designated for 0.50 AAPA Category 1 CME credits. Approval is
valid from 1/15/2021 to 1/14/2022. PAs should only claim credit commensurate
with the extent of their participation. AAPA reference number:
CME-201758.
This activity is
approved for 0.5 contact hour(s) of continuing education (which includes 0.33
hours of pharmacology) by the American Association of Nurse Practitioners.
Activity ID 20124677. This activity was planned in accordance with AANP
Accreditation Standards and Policies.
This enduring material is approved for 1 year from the date of original release, January 15, 2021 through January 14, 2022.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate, AANP Contact Hours Certificate, or AAPA Category 1 CME Credit Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, Inc.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com.
Activity Details
ABIM/AAFP/AANP/AAPA
Expires: January 14, 2022
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is family practice physicians, internists, pediatricians, physician assistants, nurse practitioners, and other health care professionals involved in the management of patients with influenza.
Learning Objectives
Upon successful completion of this educational activity, participants should be better able to:
- Diagnose patients with influenza infection by using guideline recommendations and best practices.
- Distinguish antiviral treatments for influenza based on their efficacy, safety, and ability to reduce viral shedding.
- Select the most appropriate treatment for patients diagnosed with influenza who are at normal or high risk for complications.
- Assess the use of antiviral prophylaxis in people who have been exposed to influenza infection.
Activity Description
While the impact of influenza varies, it places a substantial burden on the health of people in the United States each year. The Centers for Disease Control and Prevention (CDC) estimates that influenza has resulted in between 9.2 million and 35.6 million illnesses, between 140,000 and 710,000 hospitalizations, and between 12,000 and 56,000 deaths annually since 2010. There is a need for better treatments for patients with influenza infection, preventative measures, and better mitigation for the impact associated with a pandemic. Antivirals with different targets as well as different mechanisms of action provide multiple therapeutic options, and hold promise in improving treatment effectiveness. Family physicians and advanced practice clinicians are integral for the expedient management of patients with flu. In this Wheel of Knowledge Challenge, your knowledge will be tested on the latest updates in diagnosing and managing influenza.
Activity Chair
Clinical Professor of Family and Community Medicine
Sidney Kimmel Medical College
Thomas Jefferson University
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA
Disclosure
Consulting Fee: Bayer, GlaxoSmithKline, Sanofi Pasteur
Speakers Bureau: Sanofi Pasteur
Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.
Linda A. Giarraputo, PA-C
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of
this CME activity enables the participant to earn up to 0.50 Medical
Knowledge MOC points in the American Board of Internal Medicine’s (ABIM)
Maintenance of Certification (MOC) program. It is the CME activity provider’s
responsibility to submit participant completion information to ACCME for the
purpose of granting ABIM MOC credit.
Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.
The AAFP has reviewed
Incorporating Influenza Treatment Paradigms that Reduce Complications: A
Wheel of Knowledge Challenge and deemed it acceptable for up to 0.50 Enduring
Materials, Self-Study AAFP Prescribed credit. Term of Approval is from
1/15/2021 to 1/14/2022. Physicians should claim only the credit commensurate
with the extent of their participation in the activity.
This activity has been
reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria.
This activity is designated for 0.50 AAPA Category 1 CME credits. Approval is
valid from 1/15/2021 to 1/14/2022. PAs should only claim credit commensurate
with the extent of their participation. AAPA reference number:
CME-201758.
This activity is
approved for 0.5 contact hour(s) of continuing education (which includes 0.33
hours of pharmacology) by the American Association of Nurse Practitioners.
Activity ID 20124677. This activity was planned in accordance with AANP
Accreditation Standards and Policies.
This enduring material is approved for 1 year from the date of original release, January 15, 2021 through January 14, 2022.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate, AANP Contact Hours Certificate, or AAPA Category 1 CME Credit Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, Inc.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com.
Case in Point™ Case Challenges in HIV Medicine: Benefits, Barriers, & Best Practices in an Advancing Field - Rapid ART Protocols As a New Standard of Care in HIV
StartActivity Details
0.5 Contact Hour(s)
Expires: January 8, 2022
Statement of Commercial Support
Supported by an independent educational grant from Gilead Sciences, Inc.
Provided By
This activity is jointly provided by Postgraduate Institute for Medicine and Integritas Communications.
Target Audience
This activity is designed to educate HIV specialists and infectious disease clinicians who are involved in the management of patients living with HIV.
Learning Objectives
Upon completion of this activity, the participant should be better able to:
- Describe the benefits of rapid antiretroviral therapy (ART) and tactics to overcome clinician and system barriers to implementation
Program Description
Since the rapid initiation of antiretroviral therapy (ART) has become more widely available, identified barriers to more widespread adoption of this approach to HIV management—whether faced by patient, provider, or health care system—now need solutions. In this case-based portion of a previous symposium, Dr. Richard Elion, along with Drs. Eric Daar, Seble Kassaye, and Leandro Mena, will elucidate appropriate treatment approaches that integrate established, streamlined models of care and demonstrate optimal implementation of rapid ART. Faculty will guide learners on the important role of patient navigators or linkage to care coordinators in assisting patients to successfully enroll at the clinic, navigate public or private health insurance or drug assistance programs to gain access to ART, and get referrals for needed support services, including counseling or housing assistance.
Within the context of these interactive cases, faculty will share relevant guideline recommendations, newly published data, and their clinical expertise.
Course Chair
Associate Clinical Professor
Department of Clinical Investigations
Whitman-Walker Health
The George Washington University
Washington, District of Columbia
Dr. Richard Elion is a clinical professor of medicine at George Washington University, as well as Research Director, HIV and HCV Research, at the Washington Health Institute, both in Washington, DC. He is the past Director of Clinical Research at Whitman-Walker Health in Washington, DC, where he focused on cutting-edge research in HIV. His tenure at Whitman-Walker Health coincided with the organization being selected in 2013 as part of the AIDS Clinical Trials Group by the National Institutes of Health. Prior to his tenure with Whitman-Walker Health, he served as Co-Director of HIV Services at Washington Free Clinic in Washington, DC, and in various research and clinical capacities in New York and Washington, DC. In addition to being an accomplished educator and clinician, Dr. Elion also develops educational programs around the United States.
Dr. Elion received his medical degree from Temple University in Philadelphia, Pennsylvania, and completed his internship and residency at Duke University in Durham, North Carolina. He also holds a master’s degree in counseling and spiritual psychology from the University of Santa Monica in Santa Monica, California.
Faculty
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Chief, HIV Services
Lundquist Institute for Biomedical Innovation
Professor of Medicine, David Geffen School of Medicine
University of California, Los Angeles
Torrance, California
Dr. Eric Daar is Interim Chair of the Department of Medicine and Chief of the Division of HIV Medicine at the Harbor-UCLA Medical Center in Torrance, California. He is also a professor of medicine at the David Geffen School of Medicine at UCLA in Los Angeles, California, as well as an investigator for the Lundquist Institute. He earned his medical degree from Georgetown University School of Medicine in Washington, DC, and completed his internship, residency, and fellowship at Cedars-Sinai Medical Center in Los Angeles. His clinical and research interests include a vast range of HIV-related issues that include pathogenesis and treatment of acute and chronic HIV infection, HIV/HCV coinfection, complications of HIV, and novel strategies for assessing and enhancing adherence to therapy. He has authored numerous articles that have been published in peer-reviewed journals and textbooks.
Associate Professor of Medicine
Department of Medicine
Division of Infectious Diseases
Georgetown University
Washington, District of Columbia
Dr. Seble Kassaye earned her medical degree from the University of Chicago Pritzker School of Medicine in Illinois before completing her residency training in internal medicine and pediatrics at Mount Sinai Medical Center in New York and her infectious disease fellowship at Stanford University Hospital in California. She also completed a master’s degree in epidemiology at Stanford University. Dr. Kassaye joined the faculty at Georgetown University in December 2012.
Dr. Kassaye’s investigative focus is on clinical and translational research related to HIV with the objective of increasing access to and uptake of effective HIV treatment and prevention modalities by the most at-risk and indigent populations. As the principal investigator of the DC MACS/WIHS Combined Cohort Study, she aims to understand how HIV contributes to comorbidities, metabolic and cardiovascular complications, and long-term treatment outcomes, along with social, psychological, and cognitive effects of HIV. Dr. Kassaye has been a practicing physician in Washington, DC, for almost a decade, including at a tertiary care academic center as well as a community-based clinic in the ward with highest HIV prevalence in southeast DC. Most of her US-based research projects are driven by questions that she identifies in the context of providing care to a highly indigent and socially vulnerable population.
Chair and Professor of Population Health Science
Professor of Medicine, Division of Infectious Diseases
Director, Center for HIV/AIDS Research, Education and Policy
The University of Mississippi Medical Center
Jackson, Mississippi
Dr. Leandro Mena is a clinician-researcher and public health advocate with expertise in the prevention and clinical management of sexually transmitted diseases (STDs) and HIV. He is founding chair of the Department of Population Health Science at the University of Mississippi Medical Center, John D. Bower School of Population Health, and professor of medicine in the Division of Infectious Diseases. He directs the Center for HIV/AIDS Research, Education and Policy at the Myrlie Evers-Williams Institute for Elimination of Health Disparities, and serves as the STD Medical Director for the state of Mississippi. He is also the Medical Director of the Five Points Clinic (Jackson’s public STD clinic) and cofounded Open Arms Healthcare Center (first LGBT clinic in Mississippi).
In recognition of his work developing a model program of culturally competent HIV prevention and care for Black men who have sex with men, which is being replicated in other clinics of the country, he was awarded the 2016 Achievement Award by the Gay and Lesbian Medical Association (GLMA). Board certified in infectious diseases, Dr. Mena is a research fellow with the Rural Center for STD/HIV Prevention (Indiana University). His interests include understanding the dynamics of HIV transmission in racial/ethnic, gender, and sexual minorities as well as the development and provision of culturally competent quality health services to these populations.
Joint Accreditation Statement
In support of improving
patient care, this activity has been planned and implemented by the
Postgraduate Institute for Medicine and Integritas Communications.
Postgraduate Institute for Medicine is jointly accredited by the
Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the health
care team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in this activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour(s).
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:
Richard A. Elion, MD
Grants/Research support: Gilead Sciences, Inc., ViiV Healthcare
Honoraria: Gilead Sciences, Inc., ViiV Healthcare
Speakers Bureau: Gilead Sciences, Inc.
Eric S. Daar, MD
Consulting Fees: Genentech Inc., Gilead Sciences, Inc., Merck Co., Inc.
Contracted Research: Gilead Sciences, Inc., Merck & Co., Inc., ViiV
Healthcare
Seble G. Kassaye, MD, MS
Nothing to disclose
Leandro A. Mena, MD, MPH
Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV
Healthcare
Contracted Research: Gilead Sciences, Inc., GlaxoSmithKline, Johnson &
Johnson, Merck & Co., Inc., Roche, TaiMed Biologics, ViiV Healthcare
The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.
Instructions to Receive Credit
There are no fees for participating and receiving CE credit for this activity. Participants must read the learning objectives and faculty disclosures and participate in the educational activity.
A statement of credit will be issued upon receipt of a completed posttest (with a score of 70% or higher) and an activity evaluation form at the conclusion of the activity.
If you have questions regarding the receipt of your certificate, please contact PIM via email at inquiries@pimed.com.
Media
Internet
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Activity Details
0.5 Contact Hour(s)
Expires: January 8, 2022
Statement of Commercial Support
Supported by an independent educational grant from Gilead Sciences, Inc.
Provided By
This activity is jointly provided by Postgraduate Institute for Medicine and Integritas Communications.
Target Audience
This activity is designed to educate HIV specialists and infectious disease clinicians who are involved in the management of patients living with HIV.
Learning Objectives
Upon completion of this activity, the participant should be better able to:
- Describe the benefits of rapid antiretroviral therapy (ART) and tactics to overcome clinician and system barriers to implementation
Program Description
Since the rapid initiation of antiretroviral therapy (ART) has become more widely available, identified barriers to more widespread adoption of this approach to HIV management—whether faced by patient, provider, or health care system—now need solutions. In this case-based portion of a previous symposium, Dr. Richard Elion, along with Drs. Eric Daar, Seble Kassaye, and Leandro Mena, will elucidate appropriate treatment approaches that integrate established, streamlined models of care and demonstrate optimal implementation of rapid ART. Faculty will guide learners on the important role of patient navigators or linkage to care coordinators in assisting patients to successfully enroll at the clinic, navigate public or private health insurance or drug assistance programs to gain access to ART, and get referrals for needed support services, including counseling or housing assistance.
Within the context of these interactive cases, faculty will share relevant guideline recommendations, newly published data, and their clinical expertise.
Course Chair
Associate Clinical Professor
Department of Clinical Investigations
Whitman-Walker Health
The George Washington University
Washington, District of Columbia
Dr. Richard Elion is a clinical professor of medicine at George Washington University, as well as Research Director, HIV and HCV Research, at the Washington Health Institute, both in Washington, DC. He is the past Director of Clinical Research at Whitman-Walker Health in Washington, DC, where he focused on cutting-edge research in HIV. His tenure at Whitman-Walker Health coincided with the organization being selected in 2013 as part of the AIDS Clinical Trials Group by the National Institutes of Health. Prior to his tenure with Whitman-Walker Health, he served as Co-Director of HIV Services at Washington Free Clinic in Washington, DC, and in various research and clinical capacities in New York and Washington, DC. In addition to being an accomplished educator and clinician, Dr. Elion also develops educational programs around the United States.
Dr. Elion received his medical degree from Temple University in Philadelphia, Pennsylvania, and completed his internship and residency at Duke University in Durham, North Carolina. He also holds a master’s degree in counseling and spiritual psychology from the University of Santa Monica in Santa Monica, California.
Faculty
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Chief, HIV Services
Lundquist Institute for Biomedical Innovation
Professor of Medicine, David Geffen School of Medicine
University of California, Los Angeles
Torrance, California
Dr. Eric Daar is Interim Chair of the Department of Medicine and Chief of the Division of HIV Medicine at the Harbor-UCLA Medical Center in Torrance, California. He is also a professor of medicine at the David Geffen School of Medicine at UCLA in Los Angeles, California, as well as an investigator for the Lundquist Institute. He earned his medical degree from Georgetown University School of Medicine in Washington, DC, and completed his internship, residency, and fellowship at Cedars-Sinai Medical Center in Los Angeles. His clinical and research interests include a vast range of HIV-related issues that include pathogenesis and treatment of acute and chronic HIV infection, HIV/HCV coinfection, complications of HIV, and novel strategies for assessing and enhancing adherence to therapy. He has authored numerous articles that have been published in peer-reviewed journals and textbooks.
Associate Professor of Medicine
Department of Medicine
Division of Infectious Diseases
Georgetown University
Washington, District of Columbia
Dr. Seble Kassaye earned her medical degree from the University of Chicago Pritzker School of Medicine in Illinois before completing her residency training in internal medicine and pediatrics at Mount Sinai Medical Center in New York and her infectious disease fellowship at Stanford University Hospital in California. She also completed a master’s degree in epidemiology at Stanford University. Dr. Kassaye joined the faculty at Georgetown University in December 2012.
Dr. Kassaye’s investigative focus is on clinical and translational research related to HIV with the objective of increasing access to and uptake of effective HIV treatment and prevention modalities by the most at-risk and indigent populations. As the principal investigator of the DC MACS/WIHS Combined Cohort Study, she aims to understand how HIV contributes to comorbidities, metabolic and cardiovascular complications, and long-term treatment outcomes, along with social, psychological, and cognitive effects of HIV. Dr. Kassaye has been a practicing physician in Washington, DC, for almost a decade, including at a tertiary care academic center as well as a community-based clinic in the ward with highest HIV prevalence in southeast DC. Most of her US-based research projects are driven by questions that she identifies in the context of providing care to a highly indigent and socially vulnerable population.
Chair and Professor of Population Health Science
Professor of Medicine, Division of Infectious Diseases
Director, Center for HIV/AIDS Research, Education and Policy
The University of Mississippi Medical Center
Jackson, Mississippi
Dr. Leandro Mena is a clinician-researcher and public health advocate with expertise in the prevention and clinical management of sexually transmitted diseases (STDs) and HIV. He is founding chair of the Department of Population Health Science at the University of Mississippi Medical Center, John D. Bower School of Population Health, and professor of medicine in the Division of Infectious Diseases. He directs the Center for HIV/AIDS Research, Education and Policy at the Myrlie Evers-Williams Institute for Elimination of Health Disparities, and serves as the STD Medical Director for the state of Mississippi. He is also the Medical Director of the Five Points Clinic (Jackson’s public STD clinic) and cofounded Open Arms Healthcare Center (first LGBT clinic in Mississippi).
In recognition of his work developing a model program of culturally competent HIV prevention and care for Black men who have sex with men, which is being replicated in other clinics of the country, he was awarded the 2016 Achievement Award by the Gay and Lesbian Medical Association (GLMA). Board certified in infectious diseases, Dr. Mena is a research fellow with the Rural Center for STD/HIV Prevention (Indiana University). His interests include understanding the dynamics of HIV transmission in racial/ethnic, gender, and sexual minorities as well as the development and provision of culturally competent quality health services to these populations.
Joint Accreditation Statement
In support of improving
patient care, this activity has been planned and implemented by the
Postgraduate Institute for Medicine and Integritas Communications.
Postgraduate Institute for Medicine is jointly accredited by the
Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the health
care team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in this activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour(s).
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:
Richard A. Elion, MD
Grants/Research support: Gilead Sciences, Inc., ViiV Healthcare
Honoraria: Gilead Sciences, Inc., ViiV Healthcare
Speakers Bureau: Gilead Sciences, Inc.
Eric S. Daar, MD
Consulting Fees: Genentech Inc., Gilead Sciences, Inc., Merck Co., Inc.
Contracted Research: Gilead Sciences, Inc., Merck & Co., Inc., ViiV
Healthcare
Seble G. Kassaye, MD, MS
Nothing to disclose
Leandro A. Mena, MD, MPH
Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV
Healthcare
Contracted Research: Gilead Sciences, Inc., GlaxoSmithKline, Johnson &
Johnson, Merck & Co., Inc., Roche, TaiMed Biologics, ViiV Healthcare
The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.
Instructions to Receive Credit
There are no fees for participating and receiving CE credit for this activity. Participants must read the learning objectives and faculty disclosures and participate in the educational activity.
A statement of credit will be issued upon receipt of a completed posttest (with a score of 70% or higher) and an activity evaluation form at the conclusion of the activity.
If you have questions regarding the receipt of your certificate, please contact PIM via email at inquiries@pimed.com.
Media
Internet
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Case in Point™ Case Challenges in HIV Medicine: Benefits, Barriers, & Best Practices in an Advancing Field - Optimizing Adherence and Retention in Care in HIV
StartActivity Details
0.5 Contact Hour(s)
Expires: January 8, 2022
Statement of Commercial Support
Supported by an independent educational grant from Gilead Sciences, Inc.
Provided By
This activity is jointly provided by Postgraduate Institute for Medicine and Integritas Communications.
Target Audience
This activity is designed to educate HIV specialists and infectious disease clinicians who are involved in the management of patients living with HIV.
Learning Objectives
Upon completion of this activity, the participant should be better able to:
- Optimize ART selection for treatment initiation and medication switching according to patient characteristics and comorbidities
Program Description
In this portion of a previous case-based symposium, Dr. Richard Elion, along with Drs. Eric Daar, Seble Kassaye, and Leandro Mena, will elucidate appropriate treatment approaches that integrate established, streamlined models of care and demonstrate optimal selection of ART. Demonstrating key considerations of HIV management through cases, faculty will identify and discuss aspects of care (e.g., comorbidities, polypharmacy issues, and adverse events) associated with ART regimens in specific subpopulations, such as women or the aging population. The proliferation of treatment-switching strategies has made therapeutic selection increasingly complex; real-world cases can provide context for education on this challenging topic.
Within the context of these interactive cases, faculty will share relevant guideline recommendations, newly published data, and their clinical expertise.
Course Chair
Associate Clinical Professor
Department of Clinical Investigations
Whitman-Walker Health
The George Washington University
Washington, District of Columbia
Dr. Richard Elion is a clinical professor of medicine at George Washington University, as well as Research Director, HIV and HCV Research, at the Washington Health Institute, both in Washington, DC. He is the past Director of Clinical Research at Whitman-Walker Health in Washington, DC, where he focused on cutting-edge research in HIV. His tenure at Whitman-Walker Health coincided with the organization being selected in 2013 as part of the AIDS Clinical Trials Group by the National Institutes of Health. Prior to his tenure with Whitman-Walker Health, he served as Co-Director of HIV Services at Washington Free Clinic in Washington, DC, and in various research and clinical capacities in New York and Washington, DC. In addition to being an accomplished educator and clinician, Dr. Elion also develops educational programs around the United States.
Dr. Elion received his medical degree from Temple University in Philadelphia, Pennsylvania, and completed his internship and residency at Duke University in Durham, North Carolina. He also holds a master’s degree in counseling and spiritual psychology from the University of Santa Monica in Santa Monica, California.
Faculty
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Chief, HIV Services
Lundquist Institute for Biomedical Innovation
Professor of Medicine, David Geffen School of Medicine
University of California, Los Angeles
Torrance, California
Dr. Eric Daar is Interim Chair of the Department of Medicine and Chief of the Division of HIV Medicine at the Harbor-UCLA Medical Center in Torrance, California. He is also a professor of medicine at the David Geffen School of Medicine at UCLA in Los Angeles, California, as well as an investigator for the Lundquist Institute. He earned his medical degree from Georgetown University School of Medicine in Washington, DC, and completed his internship, residency, and fellowship at Cedars-Sinai Medical Center in Los Angeles. His clinical and research interests include a vast range of HIV-related issues that include pathogenesis and treatment of acute and chronic HIV infection, HIV/HCV coinfection, complications of HIV, and novel strategies for assessing and enhancing adherence to therapy. He has authored numerous articles that have been published in peer-reviewed journals and textbooks.
Associate Professor of Medicine
Department of Medicine
Division of Infectious Diseases
Georgetown University
Washington, District of Columbia
Dr. Seble Kassaye earned her medical degree from the University of Chicago Pritzker School of Medicine in Illinois before completing her residency training in internal medicine and pediatrics at Mount Sinai Medical Center in New York and her infectious disease fellowship at Stanford University Hospital in California. She also completed a master’s degree in epidemiology at Stanford University. Dr. Kassaye joined the faculty at Georgetown University in December 2012.
Dr. Kassaye’s investigative focus is on clinical and translational research related to HIV with the objective of increasing access to and uptake of effective HIV treatment and prevention modalities by the most at-risk and indigent populations. As the principal investigator of the DC MACS/WIHS Combined Cohort Study, she aims to understand how HIV contributes to comorbidities, metabolic and cardiovascular complications, and long-term treatment outcomes, along with social, psychological, and cognitive effects of HIV. Dr. Kassaye has been a practicing physician in Washington, DC, for almost a decade, including at a tertiary care academic center as well as a community-based clinic in the ward with highest HIV prevalence in southeast DC. Most of her US-based research projects are driven by questions that she identifies in the context of providing care to a highly indigent and socially vulnerable population.
Chair and Professor of Population Health Science
Professor of Medicine, Division of Infectious Diseases
Director, Center for HIV/AIDS Research, Education and Policy
The University of Mississippi Medical Center
Jackson, Mississippi
Dr. Leandro Mena is a clinician-researcher and public health advocate with expertise in the prevention and clinical management of sexually transmitted diseases (STDs) and HIV. He is founding chair of the Department of Population Health Science at the University of Mississippi Medical Center, John D. Bower School of Population Health, and professor of medicine in the Division of Infectious Diseases. He directs the Center for HIV/AIDS Research, Education and Policy at the Myrlie Evers-Williams Institute for Elimination of Health Disparities, and serves as the STD Medical Director for the state of Mississippi. He is also the Medical Director of the Five Points Clinic (Jackson’s public STD clinic) and cofounded Open Arms Healthcare Center (first LGBT clinic in Mississippi).
In recognition of his work developing a model program of culturally competent HIV prevention and care for Black men who have sex with men, which is being replicated in other clinics of the country, he was awarded the 2016 Achievement Award by the Gay and Lesbian Medical Association (GLMA). Board certified in infectious diseases, Dr. Mena is a research fellow with the Rural Center for STD/HIV Prevention (Indiana University). His interests include understanding the dynamics of HIV transmission in racial/ethnic, gender, and sexual minorities as well as the development and provision of culturally competent quality health services to these populations.
Joint Accreditation Statement
In support of improving
patient care, this activity has been planned and implemented by the
Postgraduate Institute for Medicine and Integritas Communications.
Postgraduate Institute for Medicine is jointly accredited by the
Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the health
care team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in this activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour(s).
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:
Richard A. Elion, MD
Grants/Research support: Gilead Sciences, Inc., ViiV Healthcare
Honoraria: Gilead Sciences, Inc., ViiV Healthcare
Speakers Bureau: Gilead Sciences, Inc.
Eric S. Daar, MD
Consulting Fees: Genentech Inc., Gilead Sciences, Inc., Merck Co., Inc.
Contracted Research: Gilead Sciences, Inc., Merck & Co., Inc., ViiV
Healthcare
Seble G. Kassaye, MD, MS
Nothing to disclose
Leandro A. Mena, MD, MPH
Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV
Healthcare
Contracted Research: Gilead Sciences, Inc., GlaxoSmithKline, Johnson &
Johnson, Merck & Co., Inc., Roche, TaiMed Biologics, ViiV Healthcare
The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.
Instructions to Receive Credit
There are no fees for participating and receiving CE credit for this activity. Participants must read the learning objectives and faculty disclosures and participate in the educational activity.
A statement of credit will be issued upon receipt of a completed posttest (with a score of 70% or higher) and an activity evaluation form at the conclusion of the activity.
If you have questions regarding the receipt of your certificate, please contact PIM via email at inquiries@pimed.com.
Media
Internet
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Activity Details
0.5 Contact Hour(s)
Expires: January 8, 2022
Statement of Commercial Support
Supported by an independent educational grant from Gilead Sciences, Inc.
Provided By
This activity is jointly provided by Postgraduate Institute for Medicine and Integritas Communications.
Target Audience
This activity is designed to educate HIV specialists and infectious disease clinicians who are involved in the management of patients living with HIV.
Learning Objectives
Upon completion of this activity, the participant should be better able to:
- Optimize ART selection for treatment initiation and medication switching according to patient characteristics and comorbidities
Program Description
In this portion of a previous case-based symposium, Dr. Richard Elion, along with Drs. Eric Daar, Seble Kassaye, and Leandro Mena, will elucidate appropriate treatment approaches that integrate established, streamlined models of care and demonstrate optimal selection of ART. Demonstrating key considerations of HIV management through cases, faculty will identify and discuss aspects of care (e.g., comorbidities, polypharmacy issues, and adverse events) associated with ART regimens in specific subpopulations, such as women or the aging population. The proliferation of treatment-switching strategies has made therapeutic selection increasingly complex; real-world cases can provide context for education on this challenging topic.
Within the context of these interactive cases, faculty will share relevant guideline recommendations, newly published data, and their clinical expertise.
Course Chair
Associate Clinical Professor
Department of Clinical Investigations
Whitman-Walker Health
The George Washington University
Washington, District of Columbia
Dr. Richard Elion is a clinical professor of medicine at George Washington University, as well as Research Director, HIV and HCV Research, at the Washington Health Institute, both in Washington, DC. He is the past Director of Clinical Research at Whitman-Walker Health in Washington, DC, where he focused on cutting-edge research in HIV. His tenure at Whitman-Walker Health coincided with the organization being selected in 2013 as part of the AIDS Clinical Trials Group by the National Institutes of Health. Prior to his tenure with Whitman-Walker Health, he served as Co-Director of HIV Services at Washington Free Clinic in Washington, DC, and in various research and clinical capacities in New York and Washington, DC. In addition to being an accomplished educator and clinician, Dr. Elion also develops educational programs around the United States.
Dr. Elion received his medical degree from Temple University in Philadelphia, Pennsylvania, and completed his internship and residency at Duke University in Durham, North Carolina. He also holds a master’s degree in counseling and spiritual psychology from the University of Santa Monica in Santa Monica, California.
Faculty
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Chief, HIV Services
Lundquist Institute for Biomedical Innovation
Professor of Medicine, David Geffen School of Medicine
University of California, Los Angeles
Torrance, California
Dr. Eric Daar is Interim Chair of the Department of Medicine and Chief of the Division of HIV Medicine at the Harbor-UCLA Medical Center in Torrance, California. He is also a professor of medicine at the David Geffen School of Medicine at UCLA in Los Angeles, California, as well as an investigator for the Lundquist Institute. He earned his medical degree from Georgetown University School of Medicine in Washington, DC, and completed his internship, residency, and fellowship at Cedars-Sinai Medical Center in Los Angeles. His clinical and research interests include a vast range of HIV-related issues that include pathogenesis and treatment of acute and chronic HIV infection, HIV/HCV coinfection, complications of HIV, and novel strategies for assessing and enhancing adherence to therapy. He has authored numerous articles that have been published in peer-reviewed journals and textbooks.
Associate Professor of Medicine
Department of Medicine
Division of Infectious Diseases
Georgetown University
Washington, District of Columbia
Dr. Seble Kassaye earned her medical degree from the University of Chicago Pritzker School of Medicine in Illinois before completing her residency training in internal medicine and pediatrics at Mount Sinai Medical Center in New York and her infectious disease fellowship at Stanford University Hospital in California. She also completed a master’s degree in epidemiology at Stanford University. Dr. Kassaye joined the faculty at Georgetown University in December 2012.
Dr. Kassaye’s investigative focus is on clinical and translational research related to HIV with the objective of increasing access to and uptake of effective HIV treatment and prevention modalities by the most at-risk and indigent populations. As the principal investigator of the DC MACS/WIHS Combined Cohort Study, she aims to understand how HIV contributes to comorbidities, metabolic and cardiovascular complications, and long-term treatment outcomes, along with social, psychological, and cognitive effects of HIV. Dr. Kassaye has been a practicing physician in Washington, DC, for almost a decade, including at a tertiary care academic center as well as a community-based clinic in the ward with highest HIV prevalence in southeast DC. Most of her US-based research projects are driven by questions that she identifies in the context of providing care to a highly indigent and socially vulnerable population.
Chair and Professor of Population Health Science
Professor of Medicine, Division of Infectious Diseases
Director, Center for HIV/AIDS Research, Education and Policy
The University of Mississippi Medical Center
Jackson, Mississippi
Dr. Leandro Mena is a clinician-researcher and public health advocate with expertise in the prevention and clinical management of sexually transmitted diseases (STDs) and HIV. He is founding chair of the Department of Population Health Science at the University of Mississippi Medical Center, John D. Bower School of Population Health, and professor of medicine in the Division of Infectious Diseases. He directs the Center for HIV/AIDS Research, Education and Policy at the Myrlie Evers-Williams Institute for Elimination of Health Disparities, and serves as the STD Medical Director for the state of Mississippi. He is also the Medical Director of the Five Points Clinic (Jackson’s public STD clinic) and cofounded Open Arms Healthcare Center (first LGBT clinic in Mississippi).
In recognition of his work developing a model program of culturally competent HIV prevention and care for Black men who have sex with men, which is being replicated in other clinics of the country, he was awarded the 2016 Achievement Award by the Gay and Lesbian Medical Association (GLMA). Board certified in infectious diseases, Dr. Mena is a research fellow with the Rural Center for STD/HIV Prevention (Indiana University). His interests include understanding the dynamics of HIV transmission in racial/ethnic, gender, and sexual minorities as well as the development and provision of culturally competent quality health services to these populations.
Joint Accreditation Statement
In support of improving
patient care, this activity has been planned and implemented by the
Postgraduate Institute for Medicine and Integritas Communications.
Postgraduate Institute for Medicine is jointly accredited by the
Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the health
care team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in this activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour(s).
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:
Richard A. Elion, MD
Grants/Research support: Gilead Sciences, Inc., ViiV Healthcare
Honoraria: Gilead Sciences, Inc., ViiV Healthcare
Speakers Bureau: Gilead Sciences, Inc.
Eric S. Daar, MD
Consulting Fees: Genentech Inc., Gilead Sciences, Inc., Merck Co., Inc.
Contracted Research: Gilead Sciences, Inc., Merck & Co., Inc., ViiV
Healthcare
Seble G. Kassaye, MD, MS
Nothing to disclose
Leandro A. Mena, MD, MPH
Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV
Healthcare
Contracted Research: Gilead Sciences, Inc., GlaxoSmithKline, Johnson &
Johnson, Merck & Co., Inc., Roche, TaiMed Biologics, ViiV Healthcare
The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.
Instructions to Receive Credit
There are no fees for participating and receiving CE credit for this activity. Participants must read the learning objectives and faculty disclosures and participate in the educational activity.
A statement of credit will be issued upon receipt of a completed posttest (with a score of 70% or higher) and an activity evaluation form at the conclusion of the activity.
If you have questions regarding the receipt of your certificate, please contact PIM via email at inquiries@pimed.com.
Media
Internet
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.